Lott Dominik, Krause Andreas, Seemayer Christian A, Strasser Daniel S, Dingemanse Jasper, Lehr Thorsten
Department of Clinical Pharmacy, Saarland University, Saarbrücken, Germany.
Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123, Allschwil, Switzerland.
Pharm Res. 2017 Mar;34(3):599-609. doi: 10.1007/s11095-016-2087-x. Epub 2016 Dec 27.
This analysis aimed at describing the effect of the selective sphingosine-1-phosphate receptor 1 modulator ponesimod on lymphocyte subsets in peripheral blood. As the involvement of different lymphocyte subsets varies among different autoimmune diseases, characterizing the effect of ponesimod on these may be beneficial in better understanding treatment effects.
Three phase 1 clinical studies in healthy human subjects were pooled. Non-linear mixed-effects modeling techniques were used to study the effect of ponesimod on lymphocyte subsets such as B cells, T helper cells, T cytotoxic cells, and natural killer cells in a qualitative and quantitative manner.
Indirect-response I models including circadian variation best described the effect of ponesimod on lymphocyte subsets. B cells and T helper cells were shown to be more affected compared to T cytotoxic cells with respect to the maximum possible reduction (100% for B and T helper cells, 95% for T cytotoxic cells) and the concentration required to reach half the maximum effect. Inter-individual variability was found to be larger for T cytotoxic compared to T helper, and B cells.
These first models for ponesimod on the level of lymphocyte subsets offer a valuable tool for the analysis and interpretation of results from ponesimod trials in autoimmune diseases.
本分析旨在描述选择性1-磷酸鞘氨醇受体1调节剂波尼莫德对外周血淋巴细胞亚群的影响。由于不同淋巴细胞亚群在不同自身免疫性疾病中的参与情况各不相同,明确波尼莫德对这些亚群的影响可能有助于更好地理解治疗效果。
汇总了三项针对健康人类受试者的1期临床研究。采用非线性混合效应建模技术,以定性和定量方式研究波尼莫德对淋巴细胞亚群(如B细胞、辅助性T细胞、细胞毒性T细胞和自然杀伤细胞)的影响。
包括昼夜变化的间接反应I模型最能描述波尼莫德对淋巴细胞亚群的影响。就最大可能降低幅度(B细胞和辅助性T细胞为100%,细胞毒性T细胞为95%)以及达到最大效应一半所需的浓度而言,B细胞和辅助性T细胞比细胞毒性T细胞受影响更大。与辅助性T细胞和B细胞相比,细胞毒性T细胞的个体间变异性更大。
这些关于波尼莫德对淋巴细胞亚群水平影响的首个模型为分析和解释自身免疫性疾病中波尼莫德试验的结果提供了有价值的工具。